Clinical Trials
49 trialsA Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
M.D. Anderson Cancer Center
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Bayer
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
LUPARPED
Fundación de investigación HM
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Northwell Health
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
CAPTEM
Northwell Health
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
RABBIT
University of Arizona
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
ADePT
Trogenix ltd
STAR-GBM
Myosin Therapeutics Inc.
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
SELECT-2CAR
Beijing Biotech
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
The Methodist Hospital Research Institute
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Jecho Biopharmaceuticals Co., Ltd.
ADVICE
Filamon LTD
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NAVIG-1
Assistance Publique - Hôpitaux de Paris
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
5G-PEARL
Institute of Cancer Research, United Kingdom
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
5G-RUBY
Institute of Cancer Research, United Kingdom
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
Clinical Study of Oncolytic Virus in Glioblastoma
Mianyang Central Hospital
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Jonsson Comprehensive Cancer Center
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Duke University
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics, Inc.
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
DLL3 CAR-T Therapy Targeting Brain Tumors
Shenzhen Geno-Immune Medical Institute
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Rznomics, Inc.
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
IA Carboplatin + Radiotherapy in Relapsing GBM
Université de Sherbrooke
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Emory University
ALA-RDTinGBM
Universität Münster
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
SignPath Pharma, Inc.
BAH2472
Essen Biotech
TCaP
Queensland Institute of Medical Research
GLUGLIO
University of Zurich
GLIOSUN
Philogen S.p.A.